Home Alzheimer’s Disease Phase III REACH2 Study Demonstrates Significant Improvements from Ruxolitinib Therapy

Phase III REACH2 Study Demonstrates Significant Improvements from Ruxolitinib Therapy

Data from the phase III REACH2 study, published in The New England Journal of Medicine, demonstrated that ruxolitinib (Jakafi) therapy led to significant improvements in efficacy outcomes in patients with steroid-refractory acute graft-versus-host disease (GVHD) compared to the best available therapy.1

REACH2 is the first phase III study of ruxolitinib in acute GVHD to have met its primary endpoint, reinforcing the findings from the previously reported phase II REACH1 study.

“Patients with acute graft-versus-host disease face life-threatening challenges with limited treatment options, particularly for the nearly half of individuals who do not respond to initial steroid therapy,” Robert Zeiser, from the University Hospital Freiburg Department of Hematology, Oncology, and Stem Cell Transplantation, said in a press release.2 “These new data from REACH2 showing superiority of…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments